In addition, no association between higher sHLA-G levels and clinicopathological features has been observed in hepatocellular carcinoma (33), colorectal cancer (77), gastric cancer (47), esophageal carcinoma (50, 51), and renal cell carcinoma (62). Here, HLA-G is linked to renal cell carcinoma.